[Image: masthead]

24-HOUR MH HOTLINE

800-644-9737

FOR EMERGENCIES ONLY

24-HOUR MH HOTLINE: 800-644-9737
FOR EMERGENCIES ONLY

Blog

Blog

Regular updates by our President, MHAUS staff, and guest contributors.

MH Readiness Feedback from Multiple Facilities
Dianne Daugherty, MHAUS Executive Director
April 17, 2017
The only requirement the Malignant Hyperthermia Association of the United States (MHAUS) will not waiver on is this:  Any facility using a trigger for malignant hyperthermia (potent volatile anesthetics and/or succinylcholine) must assure there is a sufficient supply of dantrolene sodium for injection available within 10 minutes, in whatever form …
Comments (0)
Long-term Sequelae In Patients Who Experienced a Malignant Hyperthermia Event
MHAUS Staff
December 13, 2016
Werneid K, Riazi S, Brandom BW. Presented to the International Anesthesia Research Society (IARS) 2015 In the article Survey of Long-Term Sequelae in Survivors of a Malignant Hyperthermia Reaction, 23 people responded to a survey asking about the symptoms they experienced after an MH event. The most commonly reported symptoms …
Comments (4)
Unexpected MH Deaths Without Exposure To Inhalation Anesthetics In Pediatric Patients
MHAUS Staff
December 13, 2016
Brandom, BW, & Muldoon, SM. Paediatric Anaesthesia. September 2013.It is well documented that infants, children and adolescents with certain gene mutations are susceptible to malignant hyperthermia when exposed to certain medications including succinylcholine, a muscle relaxant, and inhalation anesthetics. However, fatal, MH-like episodes have also been documented in children not …
Comments (4)
Temperature changes are not late signs of malignant hyperthermia: A NAMH Registry of MHAUS Study
Guest Contributor
December 13, 2016
Temperature changes are not late signs of malignant hyperthermia: A NAMH Registry of MHAUS Study. Larach MG, Allen GC, Brandom BW, Gronert GA, & Lehman EB. Presented to the American Society of Anesthesiologists (ASA), 2008Malignant hyperthermia poses a significant risk to affected patients. Despite modern treatment and increased availability and …
Comments (2)
Is there a link between malignant hyperthermia and exertional heat illness?
Guest Contributor
December 13, 2016
Muldoon SM, Deuster P, Brandom BW, Bunger R. Exercise and Sport Sciences Reviews, 2004It has been suggested that people who have experienced an episode of exertional heat illness may be more prone to malignant hyperthermia and vice versa due to a similar genetic mutation. Malignant hyperthermia (MH) is an anesthetic …
Comments (1)
Intraoperative Presentation of MH Leads To KD Syndrome Diagnosis
MHAUS Staff
December 8, 2016
Abstract: We present the novel case report of a child with hypotonia and dysmorphic features who developed malignant hyperthermia (MH) intraoperatively. Neurology workup revealed the presence of a known causative ryanodine receptor (RYR1) mutation for MH, c.7522C>T; p.R2508C. Furthermore, the neurology workup diagnosed the child with King-Denborough syndrome (KDS). This …
Comments (0)
Long Term Oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual
Guest Contributor
November 17, 2016
Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients.Brandom, BW, & Muldoon, SM. Paediatric Anaesthesia. September 2013.It is well documented that infants, children and adolescents with certain gene mutations are susceptible to malignant hyperthermia when exposed to certain medications including succinylcholine, a muscle relaxant, and inhalation anesthetics. However, …
Comments (0)
Honoring An MH Pioneer
Guest Contributor
November 15, 2016
Dr. Beverly Britt was a very significant contributor to important discoveries about malignant hyperthermia during her Professorship at the University of Toronto. Beverly was a dear friend of mine and was helpful to me as I started my career working with physicians; especially anesthesiologists.  Beverly died at her home in …
Comments (1)
CMS reported MH related deficiencies; are YOU ready?
MHAUS Staff
May 26, 2016
From 2011 through 2015, CMS inspection findings at various health systems revealed "deficiencies" related to MH preparedness.  ARE YOU READY FOR MH   Consider bringing one of MHAUS’ MH Experts to your facility to assure your plan of action is designed to address all areas of concern and you are …
Comments (0)
Survey of Long-Term Sequelae in Survivors of a Malignant Hyperthermia Reaction
Guest Contributor
April 6, 2016
Werneid, K., & Brandom, B. (2016). Survey of Long-Term Sequelae in Survivors of a Malignant Hyperthermia Reaction. Open Journal of Anesthesiology, 06(01), 1–7. http://doi.org/10.4236/ojanes.2016.61001 When researching malignant hyperthermia, there is ample information on causes, signs, symptoms, treatments, etc. Until now, there have been no studies examining any long term sequelae …
Comments (6)
Long Term Oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual
Guest Contributor
April 6, 2016
Butala, B. N., Kang, A., Guron, J., & Brandom, B. W. (2016). Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual. Journal of Neuromuscular Diseases, 3(1), 115–119. http://doi.org/10.3233/JND-150130 A recent case report presented a patient with a significant family history of MH who had frequent symptoms …
Comments (2)
Malignant Hyperthermia: Colleagues of a Common Cause
Guest Contributor
March 29, 2016
Ramesh M. Singa MD, MHS; Cristina G. Pamaar MD Department of Anesthesiology and Perioperative Medicine, Saint Barnabas Medical Center, Livingston, NJ 07039 American and Filipino forces came together in Iloilo City, Philippines, on 8 January 2016. The group of healthcare professionals from the United States was led by Saint …
Comments (1)
From the OR to the ER: a case of MH
Guest Contributor
February 25, 2016
Reprinted with permission from Outpatient Surgery Magazine Marsha Thornhill, MD, the director of anesthesia at the Teaneck (N.J.) Surgical Center, helped save an 18-year-old patient’s life 7 years ago. The patient was having a rhinoplasty at a 1-room office-based plastic surgery center. The case was going very well, Dr. Thornhill …
Comments (2)
President's Report 2015
Dr. Henry Rosenberg MD, CPE
January 26, 2016
By Henry Rosenberg, MDMHAUS PresidentThe year 2015 was another busy, productive year for MHAUS. Dianne Daugherty, our executive director, and her staff deserve special compliments for ensuring that MHAUS runs smoothly and meets the goals and objectives set forth by the Board of Directors. New programs are introduced on a …
Comments (0)
The New CHCT Equipment
Guest Contributor
January 25, 2016
Natalia Kraeva, PhD, MH investigation unit, Toronto, Canada The MHIU in Toronto, Canada has got a replacement for the CHCT apparatus, which had been used for the MH diagnosis for more than 35 years. The new MH measuring system, custom built for us by Biegler Medizinelektronik, Austria, fully complies …
Comments (1)
Eagle Pharmaceuticals Reports Successful Outcomes from Safety and Efficacy Study of RYANODEX for Exertional Heat Stroke
MHAUS Staff
January 21, 2016
Use of RYANODEX with Current Standard of Care (SOC) Showed Substantial Evidence of Increased Effectiveness in Treating EHS than SOC Alone Favorable Safety Data Shows No Significant Drug-Related Adverse Events in Patients Treated with RYANODEX Release Date: Thursday, December 17, 2015 6:50 am EST Dateline: WOODCLIFF LAKE, N.J. Public Company …
Comments (0)
Merck's BRIDION® (sugammadex) Receives FDA Approval
Guest Contributor
December 18, 2015
Merck’s BRIDION® (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery KENILWORTH, N.J., Dec.17, 2015 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved …
Comments (0)
New Laboratory to Offer Genetic Testing for MH Susceptibility and Related Disorders
Dr. Geogirene Vladutiu, PhD
December 8, 2015
Genetic testing for susceptibility to Malignant Hyperthermia is already offered by a number of commercial laboratories (see the MHAUS web site for details). A new laboratory, the Robert Guthrie Biochemical and Molecular Genetics Laboratory at Buffalo General Medical Center, Buffalo, New York is now offering genetic testing for MH …
Comments (0)
New drug holds potential to reduce the use of a potent MH trigger drug
Dr. Henry Rosenberg MD, CPE
November 16, 2015
Succinylcholine (Anectine) is an MH trigger. Generally injected intravenously, the drug is usually used to produce deep muscle relaxation in order to facilitate such procedures as intubation of the trachea. The onset of relaxation is very rapid and the duration is generally less than 10 minutes. Succinylcholine, introduced in the …
Comments (0)
Henry Rosenberg, M.D., Named 2014 DSA Recipient
MHAUS Staff
September 21, 2015
Please read this wonderful article about Dr. Rosenberg, the President of MHAUS. Dr. Rosenberg is receiving an award this year at the American Society of Anethesiologists Annual Meeting. Join MHAUS in honoring Dr. Henry Rosenberg as he receives the ASA's Distinguished Service Award on October 24, 2015 in San Diego, …
Comments (2)
The mission of MHAUS is to promote optimum care and
scientific understanding of MH and related disorders.